Trial Profile
A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects With Diabetes, Dyslipidemia and Hypertension
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Omzotirome (Primary)
- Indications Cardiovascular disorders; Diabetes mellitus; Dyslipidaemias; Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Torrent Pharmaceuticals
- 16 Jul 2020 Planned End Date changed from 1 Aug 2020 to 1 Aug 2022.
- 16 Jul 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2022.
- 30 Jan 2018 Status changed from not yet recruiting to recruiting.